Altimmune, Inc. (ALT) Financial Statements (2024 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments184,880190,301215,92337,24033,7198,769
Cash and cash equivalents111,097190,301115,9188,96333,7198,769
Short-term investments73,783 100,00628,277  
Restricted cash and investments343434346343,534
Receivables1734,02912,3731,6504,47110,168
Other undisclosed current assets7,7269,7621,927470548994
Total current assets:192,813204,126230,25739,39539,37223,466
Noncurrent Assets
Operating lease, right-of-use asset   904698
Property, plant and equipment1,0811,4481,0571,1041,343603
Intangible assets, net (including goodwill)12,41912,41912,82412,73213,85238,722
Intangible assets, net (excluding goodwill)12,41912,41912,82412,73213,85238,722
Other noncurrent assets61587273129184239
Total noncurrent assets:14,11514,73914,85814,66315,37839,564
TOTAL ASSETS:206,928218,865245,11554,05854,75163,030
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,0354,74412,0203,9234,4563,754
Employee-related liabilities2,313    
Accounts payable4,8042,03461218373129
Accrued liabilities3,23139611,4083,9054,0833,625
Debt     7250
Business combination, contingent consideration, liability  6,090    
Deferred revenue and credits36
Other undisclosed current liabilities9,0197,442    
Total current liabilities:17,05418,27612,0203,9234,5273,840
Noncurrent Liabilities
Long-term debt and lease obligation4,5811,4541,8281,8651,8524,575
Long-term debt, excluding current maturities4,5811,4541,8281,8651,8524,575
Liabilities, other than long-term debt   5,3902,750595,938
Deferred tax liabilities, net595,938
Business combination, contingent consideration, liability   5,3902,750  
Total noncurrent liabilities:4,5811,4547,2184,6151,91110,513
Total liabilities:21,63519,73019,2398,5386,43814,353
Equity
Equity, attributable to parent185,293199,135225,87645,52048,31339,396
Common stock544212
Additional paid in capital568,399497,342417,338187,915170,208121,656
Accumulated other comprehensive loss(5,227)(5,040)(5,045)(5,020)(5,040)(4,577)
Accumulated deficit(377,884)(293,171)(186,421)(137,376)(116,856)(77,685)
Other undisclosed equity      9,282
Total equity:185,293199,135225,87645,52048,31348,678
TOTAL LIABILITIES AND EQUITY:206,928218,865245,11554,05854,75163,030

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues(68)4,4108,1855,80110,33110,738
Revenue, net10,738
Gross profit:(68)4,4108,1855,80110,33110,738
Operating expenses(87,672)(101,324)(62,984)(27,266)(53,166)(62,784)
Operating loss:(87,740)(96,914)(54,799)(21,465)(42,834)(52,045)
Nonoperating income (expense)2,830(177)337886(2,487)(19)
Investment income, nonoperating2,87020332384322748
Other nonoperating income (expense)(32)(374)24152786
Interest and debt expense(8)(6)(9)(2)(297)(162)
Loss from continuing operations before equity method investments, income taxes:(84,918)(97,096)(54,471)(20,581)(45,618)(52,226)
Other undisclosed income (loss) from continuing operations before income taxes8692297162
Loss from continuing operations before income taxes:(84,910)(97,091)(54,462)(20,579)(45,321)(52,064)
Income tax benefit 197 5,417596,1505,638
Loss from continuing operations:(84,713)(97,091)(49,044)(20,520)(39,171)(46,425)
Loss before gain (loss) on sale of properties:(97,091)(49,044)(20,520)(39,171)(46,425)
Other undisclosed net income      
Net loss:(84,713)(97,091)(49,044)(20,520)(39,171)(46,425)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(84,713)(97,091)(49,044)(20,520)(39,171)(46,425)
Preferred stock dividends and other adjustments    (453)(3,308)(4,930)
Net loss available to common stockholders, diluted:(84,713)(97,091)(49,044)(20,973)(42,479)(51,355)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(84,713)(97,091)(49,044)(20,520)(39,171)(46,425)
Other comprehensive income      2,998
Other undisclosed comprehensive income (loss)(187)4(24)20  
Comprehensive loss:(84,900)(97,086)(49,069)(20,500)(39,171)(43,428)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (463) 
Comprehensive loss, net of tax, attributable to parent:(84,900)(97,086)(49,069)(20,500)(39,634)(43,428)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: